Pérez Ruiz L.
125
Coauthors
6
Documentos
Volumen de publicaciones por año
Cargando gráfico
| Año de publicación | Num. Publicaciones |
|---|---|
| 2007 | 1 |
| 2013 | 1 |
| 2016 | 2 |
| 2020 | 1 |
| 2022 | 1 |
Publicaciones por áreas de conocimiento
Cargando gráfico
| Área de conocimiento | Num. Publicaciones |
|---|---|
| Cáncer | 6 |
| Infección | 1 |
| Medicina interna | 1 |
| Psicología | 1 |
| Farmacología | 1 |
| Inmunología | 1 |
Publicaciones por áreas temáticas
Cargando gráfico
| Área temática | Num. Publicaciones |
|---|---|
| Enfermedades | 5 |
| Farmacología y terapéutica | 4 |
| Medicina y salud | 3 |
| Economía financiera | 1 |
| Otros problemas y servicios sociales | 1 |
| Problemas sociales y servicios a grupos | 1 |
Principales fuentes de datos
| Origen | Num. Publicaciones |
|---|---|
| Scopus | 6 |
| Google Scholar | 1 |
| RRAAE | 0 |
Cargando gráfico
Coautores destacados por número de publicaciones
| Coautor | Num. Publicaciones |
|---|---|
| Carmen Elena Viada | 4 |
| Macías A.E. | 3 |
| Robaina M. | 2 |
| Ramos M. | 2 |
| Tania Crombet | 2 |
| Martha M. Fors-López | 2 |
| Collazo Herrera M.M. | 1 |
| Iznaga-Escobar N. | 1 |
| Santiesteban Y. | 1 |
| Mestre B.F. | 1 |
Cargando gráfico
Top Keywords
Cargando gráfico
Publicaciones del autor
Economic evaluation of nimotuzumab treatment for head and neck cancer in Cuba
ArticleAbstract: Objective: To evaluate the efficiency of nimotuzumab in the treatment of the patients diagnosed withPalabras claves:Autores:Carmen Elena Viada, Collazo Herrera M.M., Iznaga-Escobar N., Pérez Ruiz L.Fuentes:scopusSafety of racotumomab in the treatment of patients with non-small cell lung cancer
ArticleAbstract: In Cuba, lung cancer ranks second in incidence and first in mortality. Therefore, it is necessary toPalabras claves:Adverse events, Clinical trial, Non-small cell lung cancer, RacotumomabAutores:Carmen Elena Viada, Estevez D., Gastón Y., Macías A.E., Pérez Ruiz L.Fuentes:scopusEvaluation of Nimotuzumab for the treatment of head and neck cancer: Meta-analysis of controlled trials
ArticleAbstract: Nimotuzumab, humanized monoclonal antibody, directed against the epidermal growth factor receptor: hPalabras claves:Epidermal growth factor receptor, Head and neck tumors, Humanized monoclonal antibody, nimotuzumabAutores:Aliuska Frías, Carmen Elena Viada, García L., Mabel Álvarez, Macías A.E., Mestre B.F., Osorio M., Pérez Ruiz L., Ramos M., Robaina M., Santiesteban Y., Tania Crombet, Vega A.M.Fuentes:scopusSecurity 1E10 anti-idiotypic vaccine in patients with tumors of different locations
ArticleAbstract: Cancer is a leading cause of death in Cuba and the world. Lung cancer is the leading cause of death,Palabras claves:Anti-idiotypic, Breast, Cáncer, COLON, Non-small cell lung vaccine, security, Small cell lungAutores:Alfonso S., Carmen Elena Viada, García E., Guerra P.P., Hernández M., Macías A.E., MARTHA FORS, Martha M. Fors-López, Mendoza I.C., Neninger Vinageras E., Pérez Ruiz L., Santiesteban E.R., Vázquez A.M.Fuentes:googlescopusNimotuzumab Increases the Recovery Rate of Severe and Critical COVID-19 Patients: Evaluation in the Real-World Scenario
ArticleAbstract: EGFR signaling is an important regulator of SARS-CoV induced lung damage, inflammation and fibrosis.Palabras claves:brief research report nimotuzumab, covid-19, eGFR, FIBROSIS, inflammation, Monoclonal antibody, SARS-COV-2Autores:Batista D., Cabrera L., Diaz H., Domeq M., Gorte A., Hernández A., Hernández R., Jiménez J., Jova J.H., Luaces P.L.o., Martínez A., Medel L., Pérez Ruiz L., Porto L., Ramos M., Saavedra Hernández D., Sánchez L., Tania Crombet, Travieso N., Troche M., Valdés L., Valls A.R.Fuentes:scopus